←
Nancy Lin, MD694 posts
Nancy Lin, MD avatar

Nancy Lin, MD

@nlinmd

Breast cancer specialist @DanaFarber; Director, EMBRACE MBC program. Tweets are my own and not medical advice.

◷ Joined December 2016▧ 93 Photos and videos
Sara Tolaney avatar
⟳ Nancy Lin, MD retweeted
Sara Tolaney@stolaney1·Nov 17

Incredible news to see the FDA approval of giredestrant + everolimus for HR+ MBC with ESR1m based on evERA!!! @elmayermd @DFCI_BreastOnc

LARVOL@LarvolNov 16

FDA approves giredestrant in combination with everolimus for ER-positive, HER2-neg... fda.gov/drugs/cancer-approva… clin.larvol.com/trial-detail… #LARVOL #CancerResearch #OncologyInsights #BreastCancer #EndocrineTherapy #FDAApproval @PTarantinoMD @SuyogCancer @dr_yakupergun @kazuki_nozawa

Post attachment
Dana-Farber’s Breast Oncology Center avatar
⟳ Nancy Lin, MD retweeted
Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc·Nov 10

The DATO-BASE phase 2 trial is still actively recruiting patients in: 🔹 Cohort A: ER+/HER2− breast cancer with brain metastases 🔹 Cohort B: TNBC with brain metastases More info & eligibility: clinicaltrials.gov/study/NCT… @PTarantinoMD @nlinmd

Patients with CNS disease need more. Need better therapies. Like novel ADCs! DATO-Base is the first trial I designed when I moved to DFCI, mentored by @drsarahsam & @nlinmd. It tests Dato-DXd for CNS disease, with the LMD cohort fully accrued. Results coming soon — stay tuned!

Post attachment
Nancy Lin, MD avatar
Nancy Lin, MD@nlinmd·Nov 9

Excited to kick off our annual EMBRACE webinar series designed to educate and empower people living with metastatic breast cancer … To see recordings from 2025-2026 and check out what is coming up in 2026-2027: dana-farber.org/cancer-care/…

Watch the recording of the 2026–2027 EMBRACE #MetastaticBreastCancer Forum Series featuring Drs. Sara Tolaney (@stolaney1) and Nancy Lin (@nlinmd), as they discuss the latest developments and promising research in #MBC at @DanaFarber and beyond. The presentation is followed by a Q&A moderated by Dr. Lexie Berwick. youtu.be/z_HKhsn-eOY?si=tYN6…

Nancy Lin, MD avatar
Nancy Lin, MD@nlinmd·Nov 9

Catch up on what’s current and new in treatment of ER+ metastatic breast cancer: part of our EMBRACE forum series, designed for people living with MBC.

📽️Watch: The 2026–2027 EMBRACE Metastatic Breast Cancer Forum Series: Updates in ER-Positive #MBC. Kristina Fanucci, MD, MHS, and Antonio Giordano, MD, PhD (@antgiorda), discuss treatment advances and research updates, followed by a Q&A moderated by Molly Skeffington. #MetastaticBreastCancer #BreastCancer #ERPositive youtu.be/_13qPq9w9zg?si=kHRX…

Nancy Lin, MD avatar
Nancy Lin, MD@nlinmd·Nov 9

Learn about current treatments and new options for HER2+ metastatic breast cancer: part of a patient-facing series designed to empower people living with MBC

Adrienne Waks, MD (@adawaksmd), and Ilana Schlam, MD (@IlanaSchlam), present updates on current treatment approaches and emerging research in HER2-positive #MetastaticBreastCancer as part of the 2026–2027 EMBRACE #MBC Forum Series. Watch here: youtu.be/GURDRRkM0QY?si=2uGa…

Harold J. Burstein, MD, PhD, FASCO avatar
⟳ Nancy Lin, MD retweeted
Harold J. Burstein, MD, PhD, FASCO@DrHBurstein·Oct 30

Join us Tuesday, November 3rd at 2 PM Eastern time for a discussion of breast cancer updates from the ESMO 2026 meeting. Featuring remarkable @DanaFarber panel of @stolaney1 @elmayermd @antgiorda Ana Garrido-Castro, and myself. Hot takes, only! Webinar is free but registration required at the link below. dfci.zoom.us/webinar/registe…

Giampaolo Bianchini avatar
⟳ Nancy Lin, MD retweeted
Giampaolo Bianchini@BianchiniGP·Oct 24

🔥 Good news for TNBC patients with brain mets! Dato-DXd shows clinically meaningful activity in BMs ⚠️ Caveat: small TB02 subgroup, only half with active BMs (asymptomatic, untreated) 👉 Key message: after T-DXd, Dato-DXd also shows clear intracranial activity #ESMO26

Post attachmentPost attachmentPost attachmentPost attachment
Ilana Schlam avatar
⟳ Nancy Lin, MD retweeted
Ilana Schlam@IlanaSchlam·Oct 9

One more week to complete our survey! We want to understand what clinicians need to bring ctDNA MRD testing into routine clinical practice. If you care for patients with breast cancer, please take a few minutes to participate and help shape future research! @nlinmd @stolaney1

Dr. Ilana Schlam (@IlanaSchlam) discussing her new #ctDNA study at the HCC #BreastCancerResearchRetreat. The study is on the use of ctDNA NGS and MRD Assays in Clinical Practice. If you are a licensed clinician who treats patients with #BreastCancer, help us better understand current practice patterns and perceptions regarding the use of circulating tumor DNA (ctDNA) standard next-generation sequencing (#NGS) assays and minimal residual disease (#MRD) assays in breast cancer, across both early-stage and metastatic settings. 👉Study Link: redcap.link/ctdna_provider

Post attachment
Nancy Lin, MD avatar
Nancy Lin, MD@nlinmd·Sep 24

Yes! Pts w/MBC need: -HER2+: effective tx post TDXD esp that treat/prevent brain mets TNBC: effective tx post Trop2 x topo1 ADC. ADC are “better chemo” but we need game changers that transform the tail of the OS curve ER+: options after 1L chemo when OS really starts to fall

Our immense desire to move every successful therapy in metastatic breast cancer to front line is stifling innovation. Also the “me too” mentality of every company buying the same drug is a challenge. Hi from the clinic, We need new targets, new payloads, new 2L and 3L options in TNBC and HeR2+ MBC!

Nancy Lin, MD avatar
Nancy Lin, MD@nlinmd·Sep 19

Very cool approach leveraging LLM to characterize toxicity and correlate with GWAS at a scale that allows discovery of novel associations!

Tour de force characterizing therapy toxicity in cancer at very large scale!

Komal Jhaveri, MD, FACP, FASCO avatar
⟳ Nancy Lin, MD retweeted
Komal Jhaveri, MD, FACP, FASCO@jhaveri_komal·Sep 18

Grateful for the growing options to treat ESR1-mutated tumors. This combination was NCCN endorsed and now FDA approved. This pace of progress is exciting for our patients — but our work is far from done! @MSKCancerCenter @OncoAlert #bcsm

Imlunestrant + Abema now @FDA ✅ based off EMBER-3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ mESR1 advanced BC! - Imlunestrant alone for mESR1 approved. - Combo⬆️ mPFS w/all comers (11.1mos vs 5.5mos) - If co-PIK3CA, Capi or this combo? #bcsm #OncTwitter @OncUpdates

Post attachment
Dana-Farber’s Breast Oncology Center avatar
⟳ Nancy Lin, MD retweeted
Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc·Aug 31

📣We are leading a study on the use of #ctDNA NGS and MRD Assays in Clinical Practice. If you are a licensed clinician who treats patients with #BreastCancer, help us better understand current practice patterns and perceptions regarding the use of circulating tumor DNA (ctDNA) standard next-generation sequencing (#NGS) assays and minimal residual disease (#MRD) assays in breast cancer, across both early-stage and metastatic settings. Our goal is to identify how these tools are currently being used, the perceived barriers to their implementation, and the evidence or resources needed to support the integration of ctDNA testing into routine clinical practice. Thank you in advance for taking our short (10-15 minutes) questionnaire! 👉Link: redcap.link/ctdna_provider For more info: DFCIBreastTrials@dfci.Harvard.edu #BreastCancerResearch #BloodTest #BloodBiopsy PI: Ilana Schlam (@IlanaSchlam)

Post attachment
Nancy Lin, MD avatar
Nancy Lin, MD@nlinmd·Aug 14

Brilliant keynote from @HendriksLizza - ‘Breaking Barriers, Redefining Brain Metastases Treatment Concepts” at #snoasco2026 -identifying pts at high risk -optimizing tx and sequencing -access- trials, molecular testing, drugs, knowledge -multiD teamwork and collaborations

Post attachmentPost attachmentPost attachmentPost attachment